deuterated oxytocin (d5OT)
Phase 2Small molecule
deuterated oxytocin (d5OT) is one of 18 small molecule programs targeting Postpartum Hemorrhage. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Postpartum Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerApproved
Pitocin
RRetrophin
Approved
Cyklokapron
AAmring
Approved
Folvite
Eli LillyApproved
Syntocinon
SShana McCormack, MD
Approved
Syntometrine
NNorth Bristol NHS Trust
Approved
IV Oxytocin
GSKPhase 3
Pabal
AACADIA Pharmaceuticals Inc.
Preclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 1
Fibrinogen Concentrate
GGold Coast Hospital and Health Service
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for deuterated oxytocin (d5OT). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Chicago